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Abstract
The epidermal growth factor receptor (EGFR) plays a key role in regulating cell proliferation, migration, and differentiation,
and aberrant EGFR signaling is implicated in a variety of cancers. EGFR signaling is triggered by extracellular ligand binding,
which promotes EGFR dimerization and activation. Ligand-binding measurements are consistent with a negatively
cooperative model in which the ligand-binding affinity at either binding site in an EGFR dimer is weaker when the other site
is occupied by a ligand. This cooperativity is widely believed to be central to the effects of ligand concentration on EGFR-
mediated intracellular signaling. Although the extracellular portion of the human EGFR dimer has been resolved
crystallographically, the crystal structures do not reveal the structural origin of this negative cooperativity, which has
remained unclear. Here we report the results of molecular dynamics simulations suggesting that asymmetrical interactions
of the two binding sites with the membrane may be responsible (perhaps along with other factors) for this negative
cooperativity. In particular, in our simulations the extracellular domains of an EGFR dimer spontaneously lay down on the
membrane in an orientation in which favorable membrane contacts were made with one of the bound ligands, but could
not be made with the other. Similar interactions were observed when EGFR was glycosylated, as it is in vivo.
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Introduction
The epidermal growth factor receptor (EGFR), a member of the
Her (ErbB) family of cell-surface receptors, is critical to a variety of
cellular processes and is implicated in the development of several
forms of cancer and other diseases [1–3]. In normal cells, EGFR
activation is initiated by the binding of extracellular ligands from
the epidermal growth factor (EGF) family [4–7], giving rise to the
formation of active EGFR dimers, which transmit intracellular
signals. It was first shown 30 years ago [8–12] that the Scatchard
plots of EGF binding to EGFR are nonlinear (concave up), which
is indicative of heterogeneous binding affinity. It has been further
suggested that the heterogeneity in EGFR ligand binding may play
an important role in determining the signaling response to
different ligand concentrations [12–14].
More recently, in a study conducted by Pike and colleagues
[15], a characterization of EGFR ligand binding based on a
simultaneous fitting of binding isotherms from cells with different
levels of EGFR expression showed that EGFR ligand binding may
be described by a simple model (shown in Fig. 1A). In this model,
which is consistent with earlier results [16], negative cooperativity
underlies the heterogeneity of EGFR ligand binding [15,16]: The
binding affinity of a ligand at one EGFR binding site is smaller
when the other site is occupied).
The structural origin of this negative cooperativity has been
unclear. The existence of two structurally distinct binding sites in
the doubly liganded dimer of Drosophila EGFR (dEGFR) [17] is
consistent with its binding cooperativity. In crystal structures of the
doubly liganded human EGFR dimer, however, the two binding
sites are structurally virtually identical [18,19]. A recent investi-
gation, based on structural and biochemical analyses [20],
suggested that the ligand-binding cooperativity may be explained
by a conformational change in the ectodomain dimer. Although it
is very plausible that such a scenario explains some of the negative
cooperativity in EGFR, it is not clear that it represents the only, or
even the main, contribution.
Here we use molecular dynamics (MD) simulations to investi-
gate the structural basis of the negative cooperativity in the ligand
binding of human EGFR. We simulated the human EGFR
ectodomain dimer anchored to a lipid membrane by EGFR
transmembrane (TM) helices. In our simulations of both singly
and doubly liganded ectodomains, the dimer began in an upright
orientation, with the dimer’s long axis perpendicular to the
membrane, then spontaneously rotated and lay down on the mem-
brane in such a way that one of the binding sites faced the
membrane, while the other faced the bulk solvent. The ligand in
the membrane-facing site developed extensive favorable interac-
tions with the membrane, and our approximate free energy
calculations suggest that these interactions contribute a significant
fraction of the ligand binding free energy. These findings are
consistent with Fo¨rster resonance energy transfer (FRET) exper-
iments [21,22], which showed that some EGFR-bound ligands are
positioned within 40 A˚ of the membrane, while others are
positioned beyond 70 A˚. In further simulations of glycosylated
EGFR ectodomains, we found that the ectodomain orientation
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and the membrane interaction of the bound ligand appear
compatible with the in vivo glycosylation of EGFR.
Based on our simulation findings, we suggest that the negative
cooperativity in human EGFR ligand binding may arise in part
from broken symmetry between the two bound ligands in an
orientation in which the ectodomain rests on the membrane.
Specifically, the simulations showed that the membrane favorably
interacts with ligands bound to EGFR ectodomains resting on the
membrane, and the results suggest that the high-affinity binding to
an unliganded EGFR dimer may be attributed to this previously
largely overlooked ligand-membrane interaction (Fig. 1A). Such a
structural explanation is supported by the experimental finding
that when high-affinity ligand binding is abolished, the distance
between bound ligands and the membrane increases [22]. The
mechanism we propose here also offers a straightforward
explanation of the observation that negative ligand-binding
cooperativity in human EGFR is observed only when the receptor
is embedded in the membrane.
Results
The two ligands bound to an EGFR dimer may interact
with the membrane differently
We first simulated a dimer of the ectodomains (domains I, II,
III, and IV) and the single-helix TM segment of EGFR. Based on
available crystal structures [18,19,23], the ectodomains were
prepared in the form of an EGF-bound, back-to-back symmetric
dimer, and the TM helices were prepared in the form of a TM
dimer, with the N-terminal GxxxG-like motifs (where G represents
glycine, or another amino acid with a small side chain) as the
dimer interface [24–26]. The ectodomains were initially posi-
tioned upright, approximately perpendicular to the membrane
(Fig. 1B). In the simulation, the ectodomains lay down toward the
membrane surface, and approximately 1.7 ms into the simulation,
one of the bound ligands developed extensive interactions with the
membrane (Fig. 1C) in a partial-resting orientation of the ecto-
domain dimer. Later in the course of the simulation, the
ectodomains lay flat on the membrane, producing a full-resting
orientation (Fig. 1D). The simulation observations are supported
by FRET measurements [21,22], which have indicated that the
EGFR ectodomain dimer may rest on the membrane. The
simulation indicates that such orientations of the ectodomains are
made possible because the linker segments between the ectodo-
mains and the TM helices are not fully rigid, as has been
previously suggested [23]. We previously simulated EGFR
ectodomain monomers tethered to membrane-embedded TM
helices. Although the ectodomain is ligand-free in the simulations,
it came to rest on the membrane from an upright orientation in
such a way that, if it were ligand-bound, the ligand would be in
contact with the membrane (Fig. 6A in ref. [26]).
Notably, the orientation of the ectodomain dimer with respect to
the membrane broke the symmetry between its two bound ligands:
One of the ligands (the membrane-facing ligand) but not the other
(the solvent-facing ligand) was in contact with the membrane
(Fig. 1C). Once the ectodomain dimer rested on the membrane, the
membrane-facing ligand developed extensive favorable interactions
with the lipids. In particular, the hydrophobic residues of the EGF
ligand, such as Pro7 and Leu8, were found to enter the hydrophobic
interior of the membrane’s extracellular leaflet (Fig. 1C, inset). As
discussed in detail in later sections, similar membrane interactions
were also observed for one of the bound ligands in two other EGFR
dimer simulations we performed.
Although it is challenging to accurately calculate biomolecular
binding free energies in simulation, generalized Born models can
often provide a rough estimate. We estimated the binding free
energy of each bound ligand using the molecular mechanics/
generalized Born volume integration (MM/GBVI) model (see
Methods) [27]. We initially calculated what we refer to as the
ligand-protein interaction energy, which is an estimate for the free
energy if there is little change in the protein structure on binding.
As shown in Fig. 1E, the simplest application of the MM/GBVI
method yields an interaction energy of an EGF ligand with EGFR
of ,80 kcal mol21. The ligand-membrane interaction energy
contributes an additional ,25 kcal mol21 to the membrane-
facing ligand but almost nothing to the solvent-facing one.
The EGF-EGFR interaction energy of over 80 kcal mol21 is
much higher than the experimental value of the EGF binding free
energy (10–15 kcal mol21 [15]). As noted above, however, the
computational quantity does not include the conformational free
energy cost incurred when EGFR adopts its ligand-bound
conformation during EGF binding. Using the structures of the
active [18,19] and inactive [26] dimers, the MM/GBVI model
estimates the cost of EGFR’s transition to the ligand-bound
conformation to be 89 kcal mol21 per monomer in the EGFR
dimer. This is qualitatively consistent with our previously reported
simulations [26], in which the ligand-bound conformation was not
stable without the EGF ligands, and it suggests that the favorable
EGF-EGFR interaction is approximately canceled out by EGFR
adopting the unfavorable ligand-bound conformation. Despite this
apparently satisfactory cancellation, we suspect that the individual
canceling terms may still be overestimates, and we regard the use
of the generalized Born model in the present context as qualitative.
To assess whether interactions with the membrane could
contribute significantly to the experimental ligand-binding free
energy, we do not only look at the large (,25 kcal mol21)
estimated binding energy, but we also look at how this energy
compares to the estimated ligand-protein interaction energy. Since
the protein-membrane energy is a substantial fraction even of the
large ligand-protein interaction energy, the generalized Born
model supports the conclusion that the membrane-facing ligand
binds to the EGFR dimer with higher affinity than does the
solvent-facing one.
Author Summary
Epidermal growth factor receptor (EGFR) molecules are of
central importance in cellular communication. Embedded
in the cell membrane, these receptors bind epidermal
growth factor (EGF) molecules outside the cell and
translate this binding into specific biochemical signals
inside the cell, which in turn trigger cell proliferation,
migration, or differentiation. EGFR dysfunction has been
implicated in a variety of cancers, and EGFR-targeting
drugs are commonly used in cancer treatments. It has
been widely assumed that the extracellular portion of an
EGFR molecule protrudes perpendicularly from the cell
membrane. In detailed, atomic-level computer simulations,
however, we find that it lies down on the membrane,
placing its EGF-binding site adjacent to the membrane
surface. We further show that EGF may interact with EGFR
in two distinct ways (with or without the involvement of
the membrane). This may explain the experimental finding
that an EGF molecule binds to EGFR more weakly at higher
EGF concentration. This phenomenon, which is a manifes-
tation of an underlying negative cooperativity, is an
important but poorly understood characteristic of EGFR
activity. In this study, we also model and analyze the
glycan chains attached to EGFR, which are integral to its
behavior in living cells.
The Origin of Ligand-Binding Cooperativity in EGFR
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Intriguingly, we found that the hydrophobic patch formed by
Pro7 and Leu8 is largely conserved in vertebrate EGF molecules
(Fig. 1F). Pro7 is especially well conserved in vertebrate EGF. Leu8
is less conserved, but this position is hydrophobic in the majority of
vertebrate EGF members despite being solvent accessible.
Interactions between the membrane and glycosylated
EGFR
In vivo, human EGFR is glycosylated on the ectodomains [28],
and 10 of the receptor’s 12 potential glycosylation sites are found
to be fully or partially occupied by a variety of large, branching
glycans [29,30]. It is conceivable that the relatively bulky glycans
may preclude an EGFR ectodomain dimer from resting on the
membrane. To test whether this is the case, we modeled and
simulated an EGFR ectodomain–TM dimer system with full
glycosylation (Fig. 2A).
We decorated the EGFR ectodomains at the 10 identified
glycosylation sites [29,30] with three types of glycans (BiS1F1,
Man6, and Man8) that are common in EGFR glycosylation (see
Methods, Fig. S1, and Table S1). The simulation shows that the
Figure 1. The ectodomain portion of the EGFR dimer lying on the membrane. (A) A schematic description of EGFR ligand binding. The basic
scheme is taken from ref. [15], but we have color coded the ligands to distinguish the free, the membrane-facing bound, and the solvent-facing
bound ligands according to the simulation findings. ‘‘L’’ and ‘‘K’’ are used to denote the association constants of EGFR dimerization and ligand
binding, respectively. The negative cooperativity is reflected in K21&K22. The ligands bound to monomers are assumed to face the membrane as
found in previous simulations of EGFR monomers (ref. [26]; see the Discussion). (B–D) Simulation of an EGFR dimer construct consisting of the
ectodomains and TM helices. One EGFR subunit is colored in shades of blue, the other in shades of red, and the two bound EGF ligands in yellow. In
the initial state (B), the ectodomain dimer is standing upright, perpendicular to the membrane. In the course of the simulation, the ectodomain dimer
approaches the membrane (C), permitting the formation of extensive interactions between one of the ligands and the membrane, resulting in the
partial-resting orientation. The EGF side chains Pro7 and Leu8 (orange) penetrate deep into the membrane, reaching the lipid tails (inset). Later in the
course of the simulation (D), the ectodomain dimer approaches closer to the membrane and lies flat on its surface, in the full-resting orientation. (E)
The free energy of each ligand’s interaction with its host receptor (EGF1, blue; EGF2, red) in a two-ligand EGFR dimer (left panel) and of its interaction
with the membrane bilayer (right panel); calculations used the MM/GBVI method. (F) The N-terminal sequences of EGF in various vertebrate species
and from a set of members of the human EGF family. The amino acids shown correspond to residues 1–10 of human EGF. The conserved Cys6 is
marked in gray and hydrophobic residues in positions 1–8 are marked in orange. Hydrophobic and aromatic residues beyond position 8 are expected
to be buried in the protein interior.
doi:10.1371/journal.pcbi.1003742.g001
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glycosylation does not disrupt the ligand-membrane contacts
(Fig. 2B) we observed in nonglycosylated EGFR. In the course of
the simulation starting from the partial-resting orientation
(Fig. 1C), the orientation of the ectodomains with respect to the
membrane remained unchanged, with the membrane-facing
ligand embedded in the membrane and the other ligand facing
the solvent. The simulation showed that, in addition to interglycan
interactions, the polar glycans interact extensively with the protein
and the lipid head groups. The flexibility of glycans allowed the
ectodomains to rest on the membrane. The glycans were found to
be distributed adjacent to the protein surfaces, rather than
protruding into the solvent (Fig. S2). The membrane-facing ligand
of the glycosylated EGFR exhibited the same degree of membrane
interactions in the simulation (Fig. 2C) as that of the nonglyco-
sylated EGFR (as indicated by the values of t= 0 in Fig. 2C). In
fact, the membrane embedding of the glycosylated-EGFR
membrane-facing ligand was slightly deeper than that of the
membrane-facing ligand in nonglycosylated EGFR.
We calculated that the membrane interaction contributes an
additional estimated,30% to the membrane-facing ligand’s MM/
GBVI binding energy but virtually nothing to that of the solvent-
facing ligand (Fig. 2C). We thus conclude that robust interaction
between EGFR-bound ligands and the membrane, which may
contribute to the heterogeneous ligand binding in an EGFR dimer,
is accessible to glycosylated as well as nonglycosylated EGFR.
The ligand in a one-ligand dimer interacts with the
membrane
Having demonstrated that the ectodomains in a two-ligand
EGFR dimer may rest on the membrane and that the two ligands
may differ in their interactions with the membrane due to the
ectodomain’s orientation, we further simulated the one-ligand
EGFR dimer. These simulations suggest that the ectodomains may
rest on the membrane and that the ligand in a one-ligand EGFR
dimer may also develop favorable interactions with the membrane,
thus providing a structural model for high-affinity binding in the
one-ligand EGFR dimer (Fig. 1A).
Because a crystal structure of a singly liganded ectodomain of an
EGFR dimer is not yet available, we made a model based on the
crystal structure of the two-ligand ectodomain dimer by removing
one bound ligand from the crystal structure [26]. We here
simulated the one-ligand ectodomain dimer in this conformation,
connected with the TM segments, three times. In all three
simulations, the ectodomain dimer, which was initially in an
upright orientation, spontaneously lay down on the membrane
(Fig. 3B), allowing the ligand to come into contact and develop
extensive interactions with the membrane. We again calculated
the MM/GBVI energy of the ligand’s interaction with the
membrane (Fig. 3C). The results suggest that the membrane
interaction is energetically favorable, and that the free energy
increase associated with the ligand’s membrane interaction is a
significant fraction of the free energy arising from its interaction
with EGFR.
The favorable nature of the ligand-membrane interaction
strongly suggests that the membrane-facing binding sites are
associated with high-affinity binding. This notion is notably
supported by the observation from FRET experiments that
abolishing the high-affinity binding leads to a significant increase
in the average distance between the ligands and the membrane [22].
Assuming a thermodynamically equilibrated system, in one-ligand
Figure 2. Simulation of fully glycosylated EGFR. (A) A fully glycosylated ectodomain dimer of EGFR. The BiS1F1, Man8, and Man6 glycans
attached to EGFR are colored by atom type (gray for carbon, red for oxygen, and blue for nitrogen). (B) The conformation at the end of the simulation
shown from two opposite directions. (C) Distance between the N terminus of each ligand (blue, membrane-facing ligand; red, solvent-facing ligand)
and the membrane surface (see Methods) in the glycosylated-EGFR simulation, and total surface area of the ligand buried due to its interactions with
the receptor and the membrane (left panels). Also shown are the results of the MM/GBVI calculations of the free energy of each ligand’s interaction
with its host receptor in the glycosylated two-ligand EGFR dimer (middle panel) and the results of similar calculations for each ligand’s interaction
with the membrane bilayer (the right panel). The membrane-facing ligand enjoys greater binding free energy, and thus higher binding affinity, than
the solvent-facing one due to the additional energy conferred by the membrane interaction.
doi:10.1371/journal.pcbi.1003742.g002
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EGFR dimers the ligands predominantly occupy the high-affinity
sites facing the membrane (Fig. 1A).
We also performed a similar simulation of a fully glycosylated,
one-ligand ectodomain dimer attached to the TM segments.
Starting form an upright conformation, the ectodomain dimer
again spontaneously lay down, with its bound ligand coming into
contact with the membrane (Fig. 3B and 3C). This simulation
suggests that a glycosylated one-ligand dimer may also prefer to
rest on the membrane in such a way that its bound ligand faces the
membrane, and that the ligand-membrane interactions are
energetically favorable
The two-ligand ectodomain dimer remains symmetric in
the simulations
A simulation study of EGFR [22] has previously suggested that
ectodomain interactions with the membrane may be at the root of
the observed negative cooperativity of ligand binding. It was
further suggested that the negative cooperativity may arise from
the ectodomain’s transition to a dEGFR-like asymmetric confor-
mation, induced by interactions with the membrane. Although our
simulations also suggest the important role of EGFR ectodomain
interactions with the membrane, our simulations did not show a
robust transition from a symmetric to an asymmetric conformation
in the ectodomain dimer. Fig. 4A shows that, other than minor
deviations due to the inherent flexibility of the loop regions, the
dimer’s two ectodomain subunits were nearly conformationally
identical in our simulations. In particular, the conformations of
domain II in the two subunits are highly similar, whereas in the
dEGFR dimer the domain II is straight in one subunit and bent in
the other, which ultimately leads to the different conformations of
the two binding sites. This is illustrated in Fig. 4B, where the angle
characterizing the bending of domain II is plotted. The angles of
the two EGFR subunits were approximately the same in our
simulations of the two-ligand dimer, much as they are in crystal
structures [18,19]. Our MM/GBVI calculation supports the
notion that the two receptors of the two-ligand EGFR dimer
maintain similar binding-site conformations while resting on the
membrane: The two ligands have comparable MM/GBVI
interaction energies with the receptors (Fig. 5B), including cases
in which the receptors are glycosylated (Fig. 2C).
On the other hand, for the one-ligand dimer, which assumes
asymmetric conformations, the angles differ significantly between the
two subunits. Similarly, in our simulations the average root-mean-
square deviation (RMSD) of the Ca atoms of domains I, II, and III
Figure 3. Simulations of the one-ligand dimer. (A) The conformation of the one-ligand ectodomain dimer obtained from a simulation
employing the crystal structure of the two-ligand dimer (PDB entry 3NJP; ref. [23]), with the ligand removed from the red subunit, as a starting state.
Domains I–IV and the EGF molecule are marked. The one-ligand dimer differs from the two-ligand dimer in the conformation of the domain IV of the
red subunit. (B) The one-ligand dimer lying down on the membrane. The ligand bound to this dimer faces the membrane. Snapshots from
simulations of the nonglycosylated and glycosylated dimers are shown. (C) The free energy of a ligand’s interaction with its host receptor in a one-
ligand EGFR dimer (upper panels) estimated using MM/GBVI, the strength of its interaction with the membrane bilayer (middle panels) estimated in
the same way, and the distance between the ligand’s N-terminus and the membrane (lower panels) in three independent simulations in which the
receptors were not glycosylated and in one additional simulation in which they were. Also shown (middle panels) is the total surface area of the
ligand buried due to its interactions with the receptor and the membrane. As indicated by these data, the additional free energy conferred by the
ligand’s membrane interaction is a significant fraction of its interaction energy with the receptor.
doi:10.1371/journal.pcbi.1003742.g003
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between the two subunits was significantly lower for the two-ligand
ectodomain dimer (2.760.3 A˚ when glycosylated and 2.660.5 A˚
when nonglycosylated) than for the one-ligand dimer (4.460.2 A˚
when glycosylated and 4.760.3 A˚ when nonglycosylated).
Variation in the orientations of the ectodomain dimer
We performed three independent simulations of the two-ligand,
nonglycosylated EGFR dimer. As discussed above, in one of these
simulations, the ectodomain dimer first assumed a partial-resting
orientation and eventually lay flat on the membrane (Fig. 1; also
shown as Simulation 1 in Fig. 5). In another simulation (Fig. 5A,
Simulation 2), the system arrived at a similar partial-resting
orientation and remained there to the end of the simulation. In the
third simulation (Fig. 5A, Simulation 3), the ectodomain dimer was
found to rest sideways on the membrane surface. What is common
to all three simulations, however, is that only one bound ligand
made extensive contact with the membrane (Fig. 5B, upper panels)
despite the variation in the orientation of the ectodomain dimer.
The buried surface area of the membrane-facing ligand was
consistently greater than that of the solvent-facing ligand (Fig. 5B):
2,3006100 A˚2 versus 1,6006100 A˚2. A substantial portion (up to
200 A˚2) of the approximately 700-A˚2 difference is due to the
embedding of Pro7 and Leu8 in the membrane. Our MM/GBVI
calculations also consistently suggest that ligand-membrane
interactions contribute a significant fraction to the free energy of
ligand-receptor binding (Fig. 5B).
Earlier FRET measurements indicated that EGF bound to
EGFR dimers falls into two groups: one in which the bound ligand
is close to the membrane, and another in which it is farther away.
Specifically, the FRET results showed that the N termini of the
EGF molecules in the ‘‘close’’ group are no more than 35–40 A˚
from the membrane, and the N termini of the EGF molecules in
the ‘‘far’’ group are no closer than 69–71 A˚ from the membrane
[21,22]. Our simulation results (Figs. 2C and 5B) agree with these
data (see the description of the distance measurements in the
Methods section) and the simulation conformations are similar to
those in the structural model proposed by Ka¨stner et al. based on
their FRET results [31]. In all of our simulations, the membrane-
facing ligands were close to the membrane surface (,10 A˚), and
thus belong to the former population. This population may also
include the solvent-facing ligands in cases in which the ectodomain
dimer rests flat on the membrane, such as at the end of Simulation
Figure 4. The two-ligand ectodomain dimer remaining symmetric in the simulations. (A) The two subunits of the ectodomain dimer, as
observed at the end of one of the simulations without glycosylation (left) and at the end of the simulation with full glycosylation (right),
superimposed using the Ca atoms of domains I–III for reference. The EGFR ectodomains I–III are shown in blue and red, and the EGF molecules bound
to them are shown in yellow and orange, respectively. (B) Domain II maintaining the same conformation in both subunits of the two-ligand EGFR
dimer. Angle W (the angle formed by Ca atoms of residues 194, 239, and 296 in EGFR, or 189, 235, and 289 in dEGFR) characterizes the bending of
domain II. This angle is different in each of the two subunits of the asymmetric two-ligand dEGFR dimer (the solid and dashed black lines; PDB entry
3LTF). The average angles in the simulations of two- and one-ligand EGFR dimers (Figs. 2, 3, and 5; labels refer to nonglycosylated EGFR simulations 1,
2, and 3, and glycosylated EGFR simulation G) are shown for each of the two subunits in blue and red (error bars correspond to the standard
deviation). The angle W is illustrated in the schematic of domains I, II, and III of EGFR on the right.
doi:10.1371/journal.pcbi.1003742.g004
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1, where the membrane distance is ,40 A˚ for the solvent-facing
ligand. The latter population, on the other hand, may consist of
the solvent-facing ligands in dimers such as those observed in
Simulations 2 and 3, as well as those in the upright dimers (with
distances of ,80–120 A˚).
Combining the observations from the simulations with those
from the FRET measurements, we suggest that it is unlikely that
the negative cooperativity of ligand binding can be attributed to a
single specific orientation of the ectodomain dimer. We instead
suggest that the cooperativity is associated with an ensemble of
ectodomain-dimer orientations, with the shared feature that the
high-affinity ligand binding occurs at the membrane-facing
binding site. This provides a straightforward explanation for the
experimental observation that abolishing high-affinity ligand
binding increases the average ligand-membrane distance [22].
Additionally, our simulations showed that free EGF molecules
may interact favorably with and be attached to the membrane
(Fig. S3). This simulation finding, combined with the observation
that Spitz ligands (which bind to dEGFR) need to be palmitoylated
(and thus attached to membrane) to activate dEGFR in vivo [32],
raises the possibility that the ligand-binding process of EGFR may
occur at the membrane surface.
Discussion
Our simulations suggest that an EGFR ectodomain dimer may
rest on the membrane, and that the interaction between a bound
ligand and the membrane may lead to a breaking of the symmetry
Figure 5. Ligand-membrane interaction in simulations of the two-ligand EGFR dimer. (A) Snapshots from the endpoints of the
simulations. The ectodomain dimers lie down on the membrane surface in a variety of ways; in each case, however, only one of the two ligands
establishes strong interactions with the membrane. (B) The free energy of each ligand’s interaction with its host receptor in a two-ligand EGFR dimer
(upper panels) estimated using MM/GBVI, the strength of its interaction with the membrane bilayer (middle panels) estimated in the same way, and
the distance between its N-terminus and the membrane (lower panels) in three independent simulations. In the middle panels, the surface area of
each ligand buried by the membrane is plotted. As shown, the membrane-facing ligand (blue) enjoys greater binding free energy, and thus higher
binding affinity, than the solvent-facing one (red) due to the additional energy conferred by the membrane interaction.
doi:10.1371/journal.pcbi.1003742.g005
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between the two ligands, thus contributing to the negative
cooperativity of EGFR ligand binding (Fig. 1A). Our investigation
is in part inspired by the FRET measurements of ligand distance
from the membrane; based on these results, the orientation of
EGFR ectodomains relative to the membrane was suggested to
affect ectodomain conformations and give rise to the negative
cooperativity [21,22,31]. The mechanism we propose here is
particularly supported by the FRET finding that abolishing high-
affinity ligand binding leads to a significant increase in the average
distance between EGFR-bound ligands and the membrane [22].
Our simulations of glycosylated EGFR (to our knowledge the first
simulations of a fully glycosylated receptor) showed that the
mechanism we propose is compatible with EGFR glycosylation: A
glycosylated ectodomain dimer may also rest on the membrane,
and the attached glycans do not preclude interactions between the
EGFR-bound ligand and the membrane.
In this investigation, we have largely focused on EGFR dimers
because they are central to the negative cooperativity of EGFR
ligand binding [14]. EGFR monomers may also bind ligands at a
high affinity comparable to that of EGFR dimers [15], but the
ectodomain structure of the ligand-bound EGFR monomer has
not yet been resolved. In previous MD simulations, we showed
that an EGFR monomer is similar to an EGFR dimer in that its
ectodomains also rest on the membrane in a way that would allow
membrane contact with the bound ligand [26]. From this
observation, which is independent of any specific conformation
of the ectodomains, it may be inferred that the high affinity of
ligand binding in EGFR monomers could also be explained by
favorable interactions between the membrane and the bound
ligands.
Our simulations suggest that the ectodomains of an EGFR
dimer may rest on the membrane and that a bound EGF ligand
may be in direct and energetically favorable contact with the
membrane. Our earlier simulations also suggest that EGFR
monomer ectodomains may also rest on the membrane [26]. This
does not imply, however, that the ectodomains are fixed on the
membrane in well-defined orientations. It is likely that, on a
timescale much longer than our simulations, the ectodomains
convert from one orientation to another in a dynamic equilibrium.
While the orientations in which the ectodomains rest on the
membrane may predominate, the ectodomains likely access the
other orientations that could be crucial to the process of ligand
binding or EGFR dimerization.
A recent study [20] proposed that a conformational change
from the so-called ‘‘flush’’ to the ‘‘staggered’’ arrangement
between the two extracellular subunits in an EGFR dimer
(Fig. 6A) may be at the root of the binding cooperativity of
EGFR. While such a binding-cooperativity mechanism differs
from the mechanism we propose here, these two mechanisms are
not mutually exclusive. In agreement with the finding of Liu et al.
[20] based on crystal structures, our simulations show that the two-
ligand EGFR dimer prefers the staggered conformation and that
the one-ligand and ligand-free EGFR dimers prefer the flush
conformation [26]. Intriguingly, the ectodomain interaction with
the membrane and the glycosylation of EGFR appear to
strengthen this trend (Fig. 6B). From this observation, we suggest
that the membrane may be of critical importance to the negative
cooperativity of EGFR ligand binding, not only for its asymmetric
interactions with the bound ligands, but also for its effect on the
accessible conformational space of the ectodomain dimers. Further
investigation is certainly needed to quantify the contribution of the
conformational dynamics of the ectodomains and the contribu-
tions of ligand-membrane interactions to the ligand-binding
cooperativity of EGFR. Further investigation would also be
needed to clarify whether the membrane interactions of the
ectodomains have any role in autoinhibition. We have not
addressed this question, but we have previously shown that the
membrane interactions of the EGFR kinase domain do play an
autoinhibitory role [25,26].
Experiments have shown that the ligand-binding cooperativity
of EGFR is apparently missing for isolated EGFR dimer
ectodomains in solution [12]. It was shown that the negative
cooperativity may be partially recovered when the membrane is
included in experiments of EGFR ectodomains attached to the
TM helices [33]. Our suggested mechanism for the negative
binding cooperativity, in which the membrane plays a central role,
offers a straightforward explanation for these findings. If the
asymmetry between the bound ligands in an EGFR dimer, and
thus the binding cooperativity, is indeed associated with the
difference in the interactions of bound ligands with the cell
membrane, the absence of the membrane would naturally
eliminate the binding cooperativity. Likewise, the lack of
cooperativity for detergent-solubilized EGFR [34] may be
explained by the absence of an extended membrane capable of
interacting with EGFR-bound ligands. It has been shown that
mutations at the intracellular domains of EGFR yield nearly linear
Scatchard plots [33]. Although these Scatchard plots could reflect
a weakened negative cooperativity due to these mutations, and
thus suggest that the root of the negative cooperativity may lie
beyond the ectodomains and the membrane, there is an
alternative explanation: that the dimerization prior to ligand
binding, which is a prerequisite of the binding cooperativity [15],
was weakened, leading to both a near-linear Scatchard plot and a
difficulty in using the plot to reliably quantify binding coopera-
tivity [20].
Our investigation of the relationship between the EGFR
ectodomains and the cell membrane using atomistic, long-
timescale MD simulations suggests a structural mechanism for
the negative cooperativity of ligand binding of EGFR dimers; in
this mechanism, the ectodomains may rest on the membrane, and
the presence of the membrane may break the symmetry between
the two binding sites. These results add further support to the
emerging view that interactions between EGFR and the mem-
brane play a central role in many aspects of the regulation of
EGFR signaling [25,26,34–36].
Methods
The simulations were performed on a special-purpose super-
computer, Anton [37], using the Amber ff99SB-ILDN [38–40]
force field, combined with the ff99SB* backbone correction [41]
for proteins, the CHARMM C36 force field [42] for lipids, and
TIP3P [43] as the water model. The simulated systems were
solvated in water with 0.15 M NaCl, with residue protonation
states corresponding to pH 7. Additional Na+ ions were included
to neutralize the net charges of the proteins (23 for the
extracellular domains of each EGFR, 24 for each EGF ligand)
and the POPS lipids. As an equilibration stage, the protein
backbone atoms were first restrained to their initial positions using
a harmonic potential with a force constant of 1 kcal mol21 A˚22.
The force constant was linearly scaled down to zero over at least
50 ns. Simulations were performed in the NPT ensemble with
T = 310 K and P = 1 bar using the MTK algorithm [44] with 20-
ps relaxation time. Water molecules and all bond lengths to
hydrogen atoms were constrained using M-SHAKE [45]. The
simulation time step was 1 fs for the equilibration stage and 2 fs for
production simulations; the r-RESPA integration method was
used, with long-range electrostatics evaluated every 6 fs [46].
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The glycosylation of EGFR was modeled based on the mass-
spectrometry analysis of the CL1-0 cell line [30], which is broadly
consistent with similar analysis on CL1-5 and A431 cell lines [29,30].
Since EGFR glycan attachments in the cell are very diverse—for
every glycosylation site there is a large number of different glycan
types that can be attached to it—we chose glycans among the most
commonly found at the specific sites. These three common types are
BiS1F1, Man6, and Man8 (Fig. S1 and Table S1). The glycan
structures for the initial models were obtained using the Glycam web
service [47] and then adjusted in VMD [48] to avoid clashes with
protein and membrane. The simulations were performed with the
GLYCAM06 force field [49] applied to the glycans.
The simulated systems included the ectodomain–TM dimers
with two EGF molecules bound (three simulations of 2.6, 1.2, and
2.1 ms; ,315,000 atoms) and with one EGF molecule bound
(three simulations of 2.5, 2.3, and 0.9 ms; ,300,000 atoms), a two-
ligand glycosylated ectodomain–TM dimer (3.0 ms; ,310,000
atoms), a one-ligand glycosylated ectodomain–TM dimer (8.3 ms;
,300,000 atoms), and a single EGF molecule (see SI; two
simulations of 8.9 and 8.3 ms; ,62,000 atoms); a membrane was
included in every case. Each system is set up such that each dimer
is at least 25 A˚ from its periodic image.
The model membrane consisted of POPC lipids, with 30%
(molar) POPC randomly replaced by POPS in the intracellular
Figure 6. ‘‘Staggered’’ and ‘‘flush’’ conformations of the extracellular dimers. (A) The staggered and flush conformations [20] are observed
in PDB entries 1IVO and 1MOX, respectively. These two conformations are shown at the top and in the middle. At the bottom, the yellow subunits of
both crystal structures are superposed and the view is from above (relative to the other two images). The conformations can be distinguished by the
angle h formed by the Ca atoms of Ile190 and Pro204 of one subunit and Pro204 of the other. (B) Distributions of h observed in simulations of the
one- (black) and two-ligand (red) EGFR dimers. Data from the simulations of ectodomains in solution, reported in ref. [26], and data from simulations
of nonglycosylated and glycosylated EGFR constructs with the membrane, which are reported in the present study, are shown from top to bottom,
respectively. Values of h from the crystal structures are indicated. Two slightly different h values are obtained for each crystal structure, because the
structures are not exactly symmetric; the spaces between these values are shown as colored bands.
doi:10.1371/journal.pcbi.1003742.g006
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leaflet of the bilayer (only for the ectodomain–TM simulations) to
approximately mimic the charge distribution in the cellular
membrane [26,50]. Modeling, analysis, and visualization were
performed using VMD [48].
The distance between the EGF N terminus and the membrane,
namely the distance from the N terminus to the plane through the
phosphates of the extracellular lipid layer, was computed in a
manner consistent with the FRET measurements [22].
The EGF-EGFR interaction energy estimation was based on
the molecular mechanics/generalized Born volume integration
(MM/GBVI) model [27] and performed using MOE software
(Chemical Computing Group) [51]. The EGF-receptor binding
energy was calculated for each snapshot from the difference of the
energy of the EGF-receptor complex and the sum of isolated EGF
and receptor energies. The EGF-membrane energy was calculated
analogously. The conformational free energy of EGFR extracel-
lular dimers was estimated based on the published coordinates of
the full-length ligand-bound and ligand-free EGFR dimers [26]
after energy minimization. Our calculations included domains I,
II, III, and IV. The MM/GBVI energy is 234287.4 kcal mol21
for the ligand-free dimer and 234110.2 kcal mol21 for the ligand-
bound dimer (the EGF ligands were not included in the
calculation), and thus the conformational free energy cost for
each monomer is 88.6 kcal mol21.
Supporting Information
Figure S1 Schematic representation of the three types
of glycans used in simulation. The glycans BiS1F1, Man8,
and Man6 [30] were attached to EGFR glycosylation sites as
described in Table S1. The schematics shown represent the
specific choices made for simulation; experimentally, there is
ambiguity in terms of which branch some sugar rings belong to
(e.g., NeuAc in BiS1F1). The attachment to the protein is on the
right.
(EPS)
Figure S2 Radius of gyration of all the glycan attach-
ments and of the EGFR EC domains in simulations of
glycosylated EGFR. The plots on the top show radius of
gyration computed for all 20 glycan attachments (excluding the
EGFR and EGF proteins), and those on the bottom show radius of
gyration for only the protein component of the EGFR ectodo-
mains. In our initial models the glycan attachments protrude from
the protein into the solvent—hence the relatively large initial
radius of gyration. In simulation, however, the glycans engage in
extensive interactions with the protein surface, resulting in a more
compact overall arrangement. This is evidenced by a significant
drop in the radius of gyration. The plots on the bottom show that
this drop is not due to conformational changes in the protein, since
the protein radius of gyration does not change significantly.
(EPS)
Figure S3 Interactions between free EGF and the
membrane. (A) Distribution of the position of the EGF’s center
along the membrane normal (‘‘z-axis’’) relative to the center of the
membrane is shown here. The panel includes data from two
independent simulations (black and red, each over 8-ms long).
Because the simulated systems are periodic, the EGF can switch
from one side of the membrane to the other by crossing the
periodic boundary. To account for this, the distributions over the
‘‘+z’’ and ‘‘2z’’ directions are combined into one distribution in
the positive direction. (B) The simulation setup is shown here. EGF
is initially placed away from the membrane, but it quickly attaches
to the membrane and occasionally inserts the hydrophobic
residues Pro7 and Leu8 into the membrane interior, as illustrated.
Positions of the EGF center for the snapshots shown are projected
on the plot. The shift between the peaks of the red and black
distributions in (A) are due to the differences in the most frequently
observed orientation of EGF with respect to the membrane in
the two independent simulations. The upper peak corresponds to
the orientation in which the long axis of EGF is perpendicular
to the membrane, as illustrated in (B), and the lower peak
corresponds to a different orientation, in which the long axis of
EGF is parallel to the membrane.
(EPS)
Table S1 Glycosylation of EGFR in simulations. Among
the 12 potential N-glycosylation sites of EGFR, two are not
glycosylated (N104 and N172). In our simulation study, we
attached one of three types of glycans—BiS1F1, Man6, or
Man8—to each asparagine side chain of the 10 remaining sites.
(DOCX)
Text S1 In the supporting information text and figures,
simulations of EGF molecules interacting with the
extracellular membrane are discussed. Also discussed, in
the SI Figures, are chemical and conformational details of the
glycans attached to EGFR in our simulations.
(DOCX)
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